Many drugs have been used to prevent and delay the progression of cardiovascular disease in T2DM patients, among which a new drug, sodium-glucose cotransporter 2 inhibitor (SGLT2i), has gradually gained attention due to its combined improvement of cardiovascular outcomes and long-term prognosis (3, 4). The gene discussed is SLC5A2; the disease is cardiovascular disorder.